A detailed history of Ballew Advisors, Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Ballew Advisors, Inc holds 1,123 shares of ABBV stock, worth $187,058. This represents 0.15% of its overall portfolio holdings.

Number of Shares
1,123
Holding current value
$187,058
% of portfolio
0.15%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$163.84 - $199.33 $183,992 - $223,847
1,123 New
1,123 $221,000
Q4 2018

Feb 12, 2019

SELL
$77.85 - $96.01 $40,559 - $50,021
-521 Closed
0 $0
Q3 2018

Oct 30, 2018

BUY
$88.91 - $98.84 $266 - $296
3 Added 0.58%
521 $42,000
Q2 2018

Jul 30, 2018

BUY
$89.78 - $106.23 $269 - $318
3 Added 0.58%
518 $48,000
Q1 2018

May 07, 2018

BUY
$92.01 - $123.21 $47,385 - $63,453
515 New
515 $49,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $295B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Ballew Advisors, Inc Portfolio

Follow Ballew Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ballew Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ballew Advisors, Inc with notifications on news.